BCR and melanoma: Among the melanoma patients undergoing checkpoint blockade, those whose baseline tumors were predicted by the model to increase BCR diversity following treatment showed higher proportions of clinical responses (including marginal, partial, and complete responses), while those predicted not to have an increase in BCR diversity had higher proportions of progressive disease (Fig. 5A).